QR Kod

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

Adoptive therapy with CD19 chimeric antigen receptor (CAR) T cells is effective against B-cell malignancies; however, T-cell activation rapidly declines, increasing the risk of early leukemia relapses. To augment CD19 CAR T-cell functionality, we interfered with the physiological control of T-cell a...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Tim Schlierkamp-Voosen, Markus Barden, Helena Janning, Marcell Kaljanac, Dennis Christoph Harrer, Celine Dreger, Kathrin Hammon, Moritz Ertelt, Clara T. Schoeder, Hólmfridur Rósa Halldórsdóttir, Carlos Rodriguez-Pardo, Sine Reker Hadrup, Simone Thomas, Hinrich Abken
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2026-04-01
Seri Bilgileri:Frontiers in Immunology
Konular:
CAR (chimeric antigen receptor)
CD19
CD30
leukemia
lymphoma
T cell
Online Erişim:https://www.frontiersin.org/articles/10.3389/fimmu.2026.1725641/full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller